Farringdon Capital’s Atossa Therapeutics ATOS Stock Holding History

Farringdon Capital’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-888	Closed	-$8.96K	–	437
2025 Q1	$8.96K	Buy	+888	New	+$10.8K	﹤0.01%	327

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Farringdon Capital's ATOS Position: Q2 2025 in Review

Farringdon Capital sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 888 shares — an estimated $8.96K sold.

Farringdon Capital first reported a position in ATOS in Q1 2025 and held it in 1 quarter. The position peaked at $8.96K in Q1 2025. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

Farringdon Capital reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
Farringdon Capital sold 888 Atossa Therapeutics shares in Q2 2025, an estimated $8.96K.
Farringdon Capital first reported a position in Atossa Therapeutics in Q1 2025 and held it in 1 quarter.
Farringdon Capital's Atossa Therapeutics position peaked at $8.96K in Q1 2025.
84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Farringdon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.